These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 26034349)

  • 1. New targeted therapies in pancreatic cancer.
    Seicean A; Petrusel L; Seicean R
    World J Gastroenterol; 2015 May; 21(20):6127-45. PubMed ID: 26034349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer.
    Koido S; Homma S; Takahara A; Namiki Y; Komita H; Uchiyama K; Ito M; Gong J; Ohkusa T; Tajiri H
    Immunotherapy; 2012 Jan; 4(1):5-7. PubMed ID: 22149993
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
    Matsuoka T; Yashiro M
    World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Treatment Strategies in Pancreatic Cancer.
    Trunk A; Miotke L; Nevala-Plagemann C; Verdaguer H; Macarulla T; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):773-787. PubMed ID: 34398070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic targets for pancreatic cancer.
    Tang SC; Chen YC
    World J Gastroenterol; 2014 Aug; 20(31):10825-44. PubMed ID: 25152585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
    Garrido-Laguna I; Hidalgo M
    Nat Rev Clin Oncol; 2015 Jun; 12(6):319-34. PubMed ID: 25824606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.
    Chiu JW; Wong H; Leung R; Pang R; Cheung TT; Fan ST; Poon R; Yau T
    Oncologist; 2014 Sep; 19(9):937-50. PubMed ID: 25117068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
    Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
    Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.
    Delitto D; Vertes-George E; Hughes SJ; Behrns KE; Trevino JG
    World J Gastroenterol; 2014 Jul; 20(26):8458-70. PubMed ID: 25024602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
    Iida M; Harari PM; Wheeler DL; Toulany M
    Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted agents in the management of small cell lung cancer - present and future.
    Srivastava R; Lebowicz Y; Jamil MO
    Drugs Today (Barc); 2018 Aug; 54(8):479-488. PubMed ID: 30209442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
    Wang K; Baldwin GS; Nikfarjam M; He H
    World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
    Adamska A; Domenichini A; Falasca M
    Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging therapies in unresectable and recurrent gastric cancer.
    Jou E; Rajdev L
    World J Gastroenterol; 2016 May; 22(20):4812-23. PubMed ID: 27239108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for Predicting Response to Anti-HER2 Agents.
    Varadan V; Sandoval M; Harris LN
    Adv Exp Med Biol; 2016; 882():155-67. PubMed ID: 26987534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
    Das S; Cardin D
    Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current progress in immunotherapy for pancreatic cancer.
    Foley K; Kim V; Jaffee E; Zheng L
    Cancer Lett; 2016 Oct; 381(1):244-51. PubMed ID: 26723878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.